shutterstock_1752057890.jpg
QProtyn Centre Panel Website.tif
shutterstock_1503567947.jpg

Is your mAb optimized for
SubQ yet?

Cutting edge, viscosity-reduction technology for
monoclonal antibodies

This patented platform technology uses GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance. 

shutterstock_1084683527.jpg

HILOPRO    Technology

TM

Upgrade your mAb from IV to SubQ.

 

Re-imagine your biologic API delivered subcutaneously in a single dose up to 375mg in a 1.5mL syringe.

Proof of concept for your mAb in
8 Weeks !

Active Senior Man

Contact Us

Thank you! We will get back to you shortly.